- **68-7-22.** Collaborative practice. (a) Each of the following terms, as used in this regulation, shall have the meaning specified in this subsection:
- (1) "Collaborative drug therapy management" and "CDTM" mean a practice of pharmacy in which a pharmacist performs certain pharmaceutical-related patient care functions for a specific patient, and the functions have been delegated to the pharmacist by a physician through a collaborative practice agreement.
- (2) "Collaborative practice agreement" and "CPA" mean a signed agreement or protocol voluntarily entered into between one or more pharmacists and one or more physicians that provides for collaborative drug therapy management.
- (3) "Pharmacist" means a person licensed, without limitation or restriction, to practice pharmacy in Kansas.
- (4) "Physician" means a person who is licensed to practice medicine and surgery in Kansas and who is a signing party to the pharmacist's CPA or update.
- (b) Any pharmacist may practice collaborative drug therapy management only pursuant to a collaborative practice agreement or update established and maintained in accordance with this regulation. Although a physician shall remain ultimately responsible for the care of the patient, each pharmacist who engages in CDTM shall be responsible for all aspects of the CDTM performed by the pharmacist.

A pharmacist shall not become a party to a CPA or update that authorizes the pharmacist to engage in any CDTM function that is not appropriate to the training and experience of the pharmacist or physician, or both. A pharmacist shall not provide CDTM to a patient if the pharmacist knows that the patient is not being treated by a physician who has signed the pharmacist's current CPA.

ATTORNEY GENERAL

DEC 08 2015

APPROVED

SEP 0 4 2015

APPROVED BY

DEPT. OF ADMINISTRATION

- (c)(1) Each CPA and update shall be dated and signed by each physician and each pharmacist. Each CPA and update shall include the following:
- (A) A statement of the general methods, procedures, and decision criteria that the pharmacist is to follow in performing CDTM;
- (B) a statement of the procedures that the pharmacist is to follow to document the CDTM decisions made by the pharmacist;
- (C) a statement of the procedures that the pharmacist is to follow to communicate to the physician either of the following:
 - (i) Each change in a patient's condition identified by the pharmacist; or
 - (ii) each CDTM decision made by the pharmacist;
- (D) a statement identifying the situations in which the pharmacist is required to initiate contact with the physician; and
- (E) a statement of the procedures to be followed by the pharmacist if an urgent situation involving a patient's health occurs, including identification of an alternative health care provider that the pharmacist should contact if the pharmacist cannot reach a physician.
- (2) A CPA shall not authorize a pharmacist to administer influenza vaccine except pursuant to K.S.A. 65-1635a, and amendments thereto.
- (d) Each CPA and update shall be reviewed and updated at least every two years. A signing pharmacist shall deliver a digital or paper copy of each CPA and update to the board within five business days after the CPA or update has been signed by all parties.

ATTORNEY GENERAL

APPROVED

DEC 0 8 2015

SEP 04 2015

APPROVED BY A

- (e) Within 48 hours of making any drug or drug therapy change to a patient's treatment, the pharmacist shall initiate contact with a physician, identifying the change.
- (f) This regulation shall not be interpreted to impede, restrict, inhibit, or impair either of the following:
- (1) Current hospital or medical care facility procedures established by the hospital or medical care facility pharmacy and either the therapeutics committee or the medical staff executive committee; or
- (2) the provision of medication therapy management as defined by the centers for medicare and medicaid services under the medicare part D prescription drug benefit.
- (g) As part of each pharmacist's application to renew that individual's license, the pharmacist shall advise the board if the pharmacist has entered into a CPA. (Authorized by K.S.A. 65-1630; implementing K.S.A. 2015 Supp. 65-1626a; effective P-

.)

ATTORNEY GENERAL

DEC 0 8 2015

APPROVED BY

APPROVED

NOV 0 6 2015

DEPT. OF ADMINISTRATION